LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the pertussis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat pertussis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Pertussis: Market overview
Pertussis is a highly contagious respiratory disease and is also known as whooping cough. The Bordetella pertussis bacterium is the causing agent of pertussis. When infected by pertussis, patients suffer from uncontrollable, violent coughing, which often makes it difficult to breathe. After coughing, someone with pertussis often needs to take deep breaths, which results in a whooping sound. People of all ages can be affected by pertussis, but it can be very serious, even deadly, for infants aged less than 1 year. People with pertussis usually spread the disease to another person by coughing or sneezing, or when spending a lot of time near one another where they share the breathing space. Many babies with pertussis are infected by older siblings, parents, or caregivers, who are unaware that they have this disease.
According to a senior market research analyst at Technavio, “People who are infected with pertussis are most contagious up to 2 weeks after the cough begins. Antibiotics may shorten the amount of time someone is contagious. Vaccination in the appropriate age and time is the best treatment available for pertussis.”
Pertussis: Segmentation analysis
This drug pipeline analysis report segments the pertussis market based on therapies employed (monotherapy and combination therapy), RoA (intramuscular, intranasal, subcutaneous, epicutaneous, and intravenous), therapeutic modality (vaccine, antibody, and monoclonal antibody), targets (pertussis toxin, Th17, FHA, and PNAG), MoA (immunostimulant, anti-pertussis antibody formation, Th1 systemic immunity, and PNAG inhibitor), geographical segmentation (APAC, Americas, and EMEA) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on mechanism of action, around 69% of the molecules that are being investigated for the treatment of pertussis are immunostimulant.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.